Rustem Gafanov

5PUBLICATIONS
35CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 05, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara

|Jun 08, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh

|Jun 08, 2021
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.

Daniel P Petrylak, Raffaele Ratta, Rustem Gafanov

|Feb 02, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.

David F McDermott, Jae-Lyun Lee, Marek Ziobro

|Feb 02, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.

David F McDermott, Jae-Lyun Lee, Georg A Bjarnason

Pageof 1

Frequent Collaborators

3 joint publications

Jae-Lyun Lee

3 joint publications

Charles Schloss

2 joint publications

David F McDermott

2 joint publications

Georg A Bjarnason